Exploratory study compares imaging response assessment methods after PRRT in NET patients, suggesting implications for clinical outcomes.
Key Points
This study aims to compare imaging-based methods for assessing treatment response in neuroendocrine tumors following PRRT.
Conducted a single-center retrospective analysis of NET patients treated with PRRT from 2020 to 2024.
Evaluated five imaging response criteria post-PRRT using [68Ga]Ga-DOTATOC PET/CT.
Performed nonparametric statistical analyses to correlate imaging findings with clinical outcomes.
Thirty-one patients were evaluated post-PRRT, showing varied response rates across different imaging methods.
Functional imaging methods had higher response rates (MORE 66%, Visual PET 68%, ZP 70%) compared to RECIST (40%) and Krenning score (21%).
After a median follow-up of 37 months, 58% of patients experienced disease progression with no significant association between imaging responses and progression-free survival.